CHRISTIAN ANGERMAYER

Christian Angermayer stands as a preeminent figure in the global venture capital landscape, widely recognized for his audacious vision and commitment to pioneering technologies. As a General Partner at Presight Capital, he plays a pivotal role in identifying and nurturing companies poised to redefine industries and solve some of humanity's most pressing challenges. Presight Capital, under his influence, actively seeks out opportunities in sectors that promise transformative impact, aligning with Angermayer's long-standing philosophy of investing in the future.

Angermayer's investment focus is broad yet deeply strategic, centered on areas he believes will shape the next century. His portfolio prominently features biotech and longevity, where he champions innovations aimed at extending healthy human lifespan and combating age-related diseases. He is also a leading advocate and investor in psychedelic medicine, having been instrumental in bringing this once-taboo field into mainstream venture capital. His work in this space, particularly with companies exploring novel treatments for mental health conditions, underscores his belief in science-backed solutions for global well-being. Beyond life sciences, Angermayer actively invests in artificial intelligence, deep tech, space technology, and decentralized finance, always with an eye towards disruptive potential.

His career background is marked by an impressive entrepreneurial spirit. Angermayer is the founder of Apeiron Investment Group, his private family office, which serves as an incubator and investment vehicle for many of his ventures. Through Apeiron, he has co-founded and supported numerous successful companies across diverse sectors. This hands-on approach, combining entrepreneurial drive with strategic investment, has allowed him to build a formidable track record. He is known for his ability to spot nascent trends and back founders with the potential to create market-leading enterprises.

Among his most notable investments and ventures are ATAI Life Sciences, a biopharmaceutical company he co-founded and chairs, dedicated to developing psychedelic and non-psychedelic compounds for mental health disorders. He was also an early and significant investor in Compass Pathways, another leader in the psychedelic medicine space. These investments highlight his foresight in recognizing the therapeutic potential of psychedelics long before they gained widespread acceptance. His influence extends to other areas such as Rejuveron Life Sciences, focusing on longevity, and various ventures in fintech and crypto, demonstrating his versatile investment acumen.

Christian Angermayer's impact transcends mere financial backing; he is a thought leader who consistently advocates for innovation that serves a greater purpose. His work at Presight Capital and through Apeiron Investment Group continues to push the boundaries of what is possible, driving progress in fields critical to humanity's future. His unwavering belief in the power of technology and entrepreneurship to create a better world solidifies his position as one of the most influential investors of our time.